Valuation: Polaris Group

Market Cap 9.33B 289M 251M 234M 215M 405M 27.58B 412M 2.76B 1.08B 13.73B 1.09B 1.06B 46.04B P/E 2024
-13.6x
P/E 2025 -6.1x
Enterprise Value 9.85B 305M 265M 247M 227M 428M 29.11B 434M 2.91B 1.14B 14.49B 1.15B 1.12B 48.59B EV / Sales 2024
318x
EV / Sales 2025 603x
Free-Float
33.64%
Yield 2024 *
-
Yield 2025 -
1 day-2.25%
1 week-9.58%
1 month-19.03%
3 months-38.00%
6 months-65.00%
Current year-65.11%
1 week 10.85
Extreme 10.85
12.15
1 month 10.85
Extreme 10.85
14.15
Current year 10.85
Extreme 10.85
35.95
1 year 10.85
Extreme 10.85
44.55
3 years 10.85
Extreme 10.85
88.1
5 years 10.85
Extreme 10.85
232
10 years 9.5
Extreme 9.5
232
Manager TitleAgeSince
Director of Finance/CFO - 01/03/2019
Chief Operating Officer - 01/02/2019
Chief Executive Officer - 01/05/2014
Director TitleAgeSince
Chairman 64 24/11/2014
Director/Board Member - 25/02/2020
Director/Board Member - 03/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
-2.25%-9.58%-69.74%-87.66% 289M
-1.40%+2.59%-1.71%+11.28% 48.53B
-2.41%-0.90%+411.96%+495.33% 39.87B
-1.16%+12.96%+28.81%+7.25% 38.68B
-1.88%-3.03%+5.69%+53.00% 35.13B
-1.74%+5.12%+14.44%+41.77% 29.79B
-0.21%-4.04%+36.40%+125.75% 16.11B
-2.85%-3.92% - - 16.08B
-0.64%+2.65%+3.40%+13.11% 13.61B
-1.19%-1.32%-1.73%-34.37% 12.62B
Average -1.57%+0.07%+47.50%+69.50% 25.07B
Weighted average by Cap. -1.60%+2.02%+79.60%+108.37%

Financials

2024 2025
Net sales 107M 3.31M 2.88M 2.68M 2.46M 4.65M 316M 4.72M 31.6M 12.4M 157M 12.44M 12.17M 528M 40.6M 1.26M 1.09M 1.02M 934K 1.76M 120M 1.79M 11.99M 4.71M 59.75M 4.72M 4.62M 200M
Net income -2.5B -77.5M -67.37M -62.71M -57.57M -109M -7.4B -110M -739M -290M -3.68B -291M -285M -12.35B -3.93B -122M -106M -98.4M -90.34M -171M -11.61B -173M -1.16B -455M -5.78B -457M -447M -19.38B
Net Debt 9.19M 285K 247K 230K 211K 399K 27.17M 406K 2.71M 1.07M 13.53M 1.07M 1.05M 45.36M 517M 16.01M 13.91M 12.95M 11.89M 22.45M 1.53B 22.8M 153M 59.91M 761M 60.11M 58.79M 2.55B
Logo Polaris Group
The Polaris Group, LLC is a Cayman Islands-based company, which is primarily engaged in biotechnology services, drug testing, contract development and manufacturing services and research, development, manufacture and sales of new drugs. The Company’s core research is ADI-PEG 20, which is undergoing human clinical trials for various cancer indications. The ADI-PEG 20 is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia, and others. ADI-PEG 20 is a biological drug produced by coupling arginine deiminase and polyethylene glycol with a molecular weight of 20,000.
Employees
-
Date Price Change Volume
31/07/26 NT$10.85 -2.25% 1,885,135
30/07/26 NT$11.10 -3.90% 1,228,862
29/07/26 NT$11.55 +0.87% 1,910,566
28/07/26 NT$11.45 -3.78% 1,219,502
27/07/26 NT$11.90 -0.83% 836,358
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. 6550 Stock